Results are in, Merck’s sac-TMT meets survival endpoint in stomach cancer trial
Landon Capital News
Merck (MRK) announced that its Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech, met its primary endpoint of overall survival in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received two or more prior lines of systemic therapy.
At final analysis, sac-TMT demonstrated a statistically significant improvement in overall survival compared to treatment of physician’s choice, which consisted of trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel. Results were consistent across subgroups regardless of TROP2 expression status. The trial enrolled 473 patients.
Sac-TMT did not meet the secondary endpoint of progression-free survival assessed by blinded independent central review. The drug showed a nominally improved objective response rate compared to physician’s choice treatment, though this was not formally tested under the prespecified analysis plan. No new safety signals were observed.
About Landon Capital News
Landon Capital News is a media company that is wholly owned by Landon Capital Management LLC. Landon Capital News distributes economic, and political news in over 176 countries. Landon Capital News provides an in depth and simplistic look at financial, economic, and political news, as it is happening. We also provide our viewers with in-depth analysis on various companies and political news that directly correlate to economics. We bridge the gap of information between the investor and the markets, sectors and industries that they invest. For more information, please contact us at info@landoncapital.net or 404-995-6671 or visit https://landoncapital.net.
Safe Harbor Statement
This release does not constitute an offer to sell or a solicitation of any kind. This press release is the news that we have researched to be true and accurate to our best ability. Landon Capital does not share the sentiment of the news that is released, we are just reporting a news event. Landon Capital received no direct compensation related to this release. This release may contain certain forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof through already public resources. Actual results may differ materially from those stated or implied in.